The retinal dehydrogenase/reductase retSDR1/DHRS3 gene is activated by p53 and p63 but not by mutants derived from tumors or EEC/ADULT malformation syndromes

Cell Cycle

Volumn 9, Issue 11, 2010, Pages 2177-2188

  Kirschner, Ralf D ^a   Rother, Karen ^a   Müller, Gerd A ^a   Engeland, Kurt ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

ADULT syndrome; Development; DHRS3; EEC syndrome; Embryonal malformation; p53 p63 proteins; retSDR1; SHFM syndrome; Tumor suppression; Vitamin A

Indexed keywords

OXIDOREDUCTASE; PROTEIN P53; PROTEIN P63; RETINAL SHORT CHAIN DEHYDROGENASE REDUCTASE 1; UNCLASSIFIED DRUG;

ADULT SYNDROME; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; EEC SYNDROME; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALFORMATION SYNDROME; PHENOTYPE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; WILD TYPE;

EID: 77953601542     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.11.11844     Document Type: Article

References (61)

1. Wilson JG, Roth CB, Warkany J. An analysis of the syndrome of malformations induced by maternal vitamin A deficiency. Effects of restoration of vitamin A at various times during gestation. Am J Anat 1953; 92:189-217.
2. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008; 9:541-53. (Pubitemid 351861538)
3. Mark M, Ghyselinck NB, Chambon P. Function of retinoic acid receptors during embryonic development. Nucl Recept Signal 2009; 7:002.
4. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006; 66:606-30.
5. Pares X, Farres J, Kedishvili N, Duester G. Medium-and short-chain dehydrogenase/reductase gene and protein families : Medium-chain and short-chain dehydrogenases/ reductases in retinoid metabolism. Cell Mol Life Sci 2008; 65:3936-49.
6. Duester G. Retinoic acid synthesis and signaling during early organogenesis. Cell 2008; 134:921-31.
7. Haeseleer F, Huang J, Lebioda L, Saari JC, Palczewski K. Molecular characterization of a novel short-chain dehydrogenase/reductase that reduces all-trans-retinal. J Biol Chem 1998; 273:21790-9. (Pubitemid 28405356)
8. Bray JE, Marsden BD, Oppermann U. The human short-chain dehydrogenase/reductase (SDR) superfamily: a bioinformatics summary. Chem Biol Interact 2009; 178:99-109.
9. Cerignoli F, Guo X, Cardinali B, Rinaldi C, Casaletto J, Frati L, et al. retSDR1, a short-chain retinol dehydrogenase/ reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines. Cancer Res 2002; 62:1196-204.
10. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res 2006; 66:6080-6.
11. Niles RM. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat Res 2004; 555:81-96. (Pubitemid 39359177)
12. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, Dmitrovsky E. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 1997; 94:12070-4. (Pubitemid 27467844)
13. Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. Oncogene 1998; 16:3337-43.
14. Teixeira C, Pratt MA. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol Endocrinol 1997; 11:1191-202. (Pubitemid 28041327)
15. Chen LC, Sly L, De Luca LM. High dietary retinoic acid prevents malignant conversion of skin papillomas induced by a two-stage carcinogenesis protocol in female SENCAR mice. Carcinogenesis 1994; 15:2383-6. (Pubitemid 24317509)
16. Fujimura S, Suzumiya J, Anzai K, Ohkubo K, Hata T, Yamada Y, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 1998; 22:611-8. (Pubitemid 28327464)
17. Hsu SL, Yin SC, Liu MC, Reichert U, Ho WL. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 1999; 252:332-41. (Pubitemid 29530263)
18. Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/ p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ 2006; 13:962-72. (Pubitemid 43753487)
19. Blandino G, Dobbelstein M. p73 and p63: why do we still need them? Cell Cycle 2004; 3:886-94.
20. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356:215-21.
21. Harvey M, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, Donehower LA. Spontaneous and carcinogen- induced tumorigenesis in p53-deficient mice. Nat Genet 1993; 5:225-9. (Pubitemid 23330383)
22. Choi J, Donehower LA. p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci 1999; 55:38-47. (Pubitemid 29077853)
23. Sasai N, Yakura R, Kamiya D, Nakazawa Y, Sasai Y. Ectodermal factor restricts mesoderm differentiation by inhibiting p53. Cell 2008; 133:878-90. (Pubitemid 351707684)
24. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8:275-83.
25. Böhlig L, Metzger R, Rother K, Till H, Engeland K. The CCN3 gene coding for an extracellular adhesionrelated protein is transcriptionally activated by the p53 tumor suppressor. Cell Cycle 2008; 7:1254-61. (Pubitemid 351749280)
26. Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network. Cell Cycle 2008; 7:3291.
27. Godar S, Weinberg RA. Filling the mosaic of p53 actions: p53 represses RHAMM expression. Cell Cycle 2008; 7:3479.
28. Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle 2008; 7:3448-60.
29. Kay C, Jeyendran RS, Coulam CB. p53 tumour suppressor gene polymorphism is associated with recurrent implantation failure. Reprod Biomed Online 2006; 13:492-6. (Pubitemid 44548783)
30. Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. Nature 2007; 450:721-4.
31. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398:708-13. (Pubitemid 29197649)
32. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398:714-8. (Pubitemid 29197650)
33. Yang A, McKeon F. p63 and p73: p53 mimics, menaces and more. Nat Rev Mol Cell Biol 2000; 1:199-207.
34. Vigano MA, Lamartine J, Testoni B, Merico D, Alotto D, Castagnoli C, et al. New p63 targets in keratinocytes identified by a genome-wide approach. EMBO J 2006; 25:5105-16. (Pubitemid 44658528)
35. Brunner HG, Hamel BC, van Bokhoven H. The p63 gene in EEC and other syndromes. J Med Genet 2002; 39:377-81.
36. Rinne T, Brunner HG, van Bokhoven H. p63-associated disorders. Cell Cycle 2007; 6:262-8.
37. van Bokhoven H, Hamel BC, Bamshad M, Sangiorgi E, Gurrieri F, Duijf PH, et al. p63 Gene mutations in eec syndrome, limb-mammary syndrome, and isolated split hand-split foot malformation suggest a genotype-phenotype correlation. Am J Hum Genet 2001; 69:481-92. (Pubitemid 32777688)
38. van Bokhoven H, Brunner HG. Splitting p63. Am J Hum Genet 2002; 71:1-13.
39. Dietz S, Rother K, Bamberger C, Schmale H, Mössner J, Engeland K. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73. FEBS Lett 2002; 525:93-9.
40. Kirschner RD, Sänger K, Müller GA, Engeland K. Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site. Nucleic Acids Res 2008; 36:2969-80. (Pubitemid 351737189)
41. Deyoung MP, Ellisen LW. p63 and p73 in human cancer: defining the network. Oncogene 2007; 26:5169-83.
42. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P, Caron dF. The expression of TA and DeltaNp63 are regulated by different mechanisms in liver cells. Oncogene 2005; 24:512-9.
43. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, Struhl K. Relationships between p63 binding, DNA sequence, transcription activity and biological function in human cells. Molecular Cell 2006; 24:593-602. (Pubitemid 350284225)
44. Kawaguchi R, Yu J, Honda J, Hu J, Whitelegge J, Ping P, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315:820-5. (Pubitemid 46255829)
45. Pasutto F, Sticht H, Hammersen G, Gillessen-Kaesbach G, Fitzpatrick DR, Nurnberg G, et al. Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia and mental retardation. Am J Hum Genet 2007; 80:550-60. (Pubitemid 46310988)
46. Oler G, Camacho CP, Hojaij FC, Michaluart P Jr, Riggins GJ, Cerutti JM. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008; 14:4735-42.
47. Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, Bogdanova TI, et al. Copy Number and Gene Expression Alterations in Radiation-Induced Papillary Thyroid Carcinoma from Chernobyl Pediatric Patients. Thyroid 2009; In press.
48. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, et al. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer 2008; 98:1380-8.
49. Kamei N, Hiyama K, Yamaoka H, Kamimatsuse A, Onitake Y, Sueda T, Hiyama E. Evaluation of genes identified by microarray analysis in favorable neuroblastoma. Pediatr Surg Int 2009; 25:931-7.
50. Langenfeld J, Lonardo F, Kiyokawa H, Passalaris T, Ahn MJ, Rusch V, Dmitrovsky E. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E downregulation. Oncogene 1996; 13:1983-90. (Pubitemid 26397458)
51. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe SW, et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol 2009; 11:1451-7.
52. Marletaz F, Holland LZ, Laudet V, Schubert M. Retinoic acid signaling and the evolution of chordates. Int J Biol Sci 2006; 2:38-47.
53. Staab CA, Ceder R, Roberg K, Grafstrom RC, Hoog JO. Serum-responsive expression of carbonyl-metabolizing enzymes in normal and transformed human buccal keratinocytes. Cell Mol Life Sci 2008; 65:3653-63.
54. van Bokhoven H, McKeon F. Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. Trends Mol Med 2002; 8:133-9.
55. Ianakiev P, Kilpatrick MW, Toudjarska I, Basel D, Beighton P, Tsipouras P. Split-hand/split-foot malformation is caused by mutations in the p63 gene on 3q27. Am J Human Genet 2000; 67:59-66. (Pubitemid 30481544)
56. Khokhar SK, Kommagani R, Kadakia MP. Differential effects of p63 mutants on transactivation of p53 and/ or p63 responsive genes. Cell Res 2008; 18:1061-73.
57. Rinne T, Hamel B, van Bokhoven H, Brunner HG. Pattern of p63 mutations and their phenotypes - update. Am J Med Genet A 2006; 140:1396-406. (Pubitemid 43993130)
58. Rother K, Johne C, Spiesbach K, Haugwitz U, Tschöp K, Wasner M, et al. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 2004; 23:3376-84. (Pubitemid 38669827)
59. Krause K, Wasner M, Reinhard W, Haugwitz U, Lange-zu Dohna C, Mössner J, Engeland K. The tumour suppressor protein p53 can repress transcription of cyclin B. Nucleic Acids Res 2000; 28:4410-8.
60. Contente A, Dittmer A, Koch MC, Roth J, Dobbelstein M. A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat Genet 2002; 30:315-20.
61. Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. c-Myc target gene specificity is determined by a post- DNA binding mechanism. Proc Natl Acad Sci USA 1998; 95:13887-92. (Pubitemid 28523068)